Novo Nordisk's weight loss injection cut obesity in young children, trial shows
Get Quartz in your inbox
Free daily briefing on global business news.
Novo Nordisk's weight loss injection cut obesity in young children, trial shows
In the STEP Young trial, BMI fell an estimated 17.4% with semaglutide and rose 2.2% with placebo at week 68 among children 6 to under 12
NurPhoto / Getty Images
Novo Nordisk shared results on Monday from a Phase 3 trial showing its once-weekly semaglutide injection, sold as Wegovy, lowered body mass index in children ages 6 to under 12 with obesity. The company presented the STEP Young data at ObesityWeek 2026 and published them in The New England Journal of Medicine.
At week 68, estimated BMI fell 17.4% from baseline among children taking semaglutide and rose 2.2% among those on placebo, assuming all children stayed on treatment, the company said. The estimated difference was 19.7 percentage points. Counting all children........
